Continuous but not pulsed low-dose fetal betamethasone exposures extend the durability of antenatal steroid therapy

Tsukasa Takahashi, Yuki Takahashi, Erin L. Fee, Masatoshi Saito, Nobuo Yaegashi, Haruo Usuda, James P. Bridges, Mark A. Milad, Lucy Furfaro, Sean Carter, Augusto F. Schmidt, John P. Newnham, Alan H. Jobe, Matthew W. Kemp

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Antenatal steroid (ANS) therapy is the standard care for women at imminent risk of preterm labor. Despite extensive and long-standing use, 40%-50% of babies exposed antenatally to steroids do not derive benefit; remaining undelivered 7 days or more after ANS treatment is associated with a lack of treatment benefit and increased risk of harm. We used a pregnant sheep model to evaluate the impact of continuous versus pulsed ANS treatments on fetal lung maturation at an extended, 8-day treatment to delivery interval. Continuous low-dose ANS treatments for more than 72 h in duration improved fetal lung maturation at 8 days after treatment initiation. If fetal ANS exposure was interrupted, the beneficial ANS effect was lost. Truncated treatments, including that simulating the current clinical treatment regimen, did not improve lung function. Variable fetal lung maturation was correlated to the amount of saturated phosphatidylcholine present in the lung fluid. These data demonstrate that 1) the durability of ANS therapy may be enhanced by employing an extended, low-dose treatment regimen by reducing total dose and 2) interrupting the continuity of fetal exposure by allowing it to fall below a minimal threshold was associated with comparably poor functional maturation of the preterm ovine lung.

Original languageEnglish
Pages (from-to)L784-L793
JournalAmerican journal of physiology. Lung cellular and molecular physiology
Volume322
Issue number6
DOIs
Publication statusPublished - 1 Jun 2022

Fingerprint

Dive into the research topics of 'Continuous but not pulsed low-dose fetal betamethasone exposures extend the durability of antenatal steroid therapy'. Together they form a unique fingerprint.

Cite this